Overview

This trial is active, not recruiting.

Condition infection, human immunodeficiency virus
Treatments gsk1349572, raltegravir, gsk1349572 placebo, raltegravir placebo
Phase phase 3
Sponsor ViiV Healthcare
Collaborator Shionogi
Start date October 2010
End date February 2013
Trial size 724 participants
Trial identifier NCT01231516, 111762

Summary

ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected antiretroviral experienced, integrase-naïve subjects. Subjects will be randomized 1:1 to receive GSK1349572 50 mg once daily or raltegravir (RAL) 400 mg twice daily, each added to an investigator selected background regimen consisting of at least one fully active agent plus no more than one second single agent which may or may not be active. Antiviral activity, safety, pharmacokinetics (PK), and development of viral resistance will be evaluated.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
Subjects will receive GSK1349572 50mg once daily plus raltegravir placebo twice daily.
gsk1349572
50mg once daily
raltegravir placebo
Inactive placebo tablet twice daily
(Active Comparator)
Subjects will receive raltegravir 400mg twice daily plus GSK1349572 placebo once daily.
raltegravir
400mg twice daily
gsk1349572 placebo
Inactive placebo tablet once daily

Primary Outcomes

Measure
Percentage of Participants With HIV-1 RNA <50 Copies/Milliliter (c/mL) at Week 48
time frame: Week 48

Secondary Outcomes

Measure
Number of Participants (Par.) With Detectable Virus That Has Genotypic or Phenotypic Evidence of Treatment-emergent INI Resistance at Time of Protocol Defined Virology Failure (PDVF)
time frame: Baseline until PDVF up to Week 48
Number of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
time frame: Week 24
Number of Participants With Plasma HIV-1 RNA <400 c/mL at Week 24 and Week 48
time frame: Week 24, Week 48
Absolute Values and Change From Baseline in Cluster of Differentiation 4+ (CD4+) Cell Counts at Weeks 4, 8, 12, 16, 24, 32, 40, and 48
time frame: Baseline; Weeks 4, 8, 12, 16, 24, 32, 40, and 48
Number of Participants With Indicated Post-Baseline HIV-associated Conditions, Excluding Recurrences, and Disease Progressions
time frame: From Baseline (Day 1) until Week 48
Number of Participants With the Indicated Post-Baseline Emergent Grade 1 to 4 Clinical Chemistry and Hematology Toxicities/Laboratory Adverse Events (AEs)
time frame: From Baseline until Week 48, including participants with post-treatment events occurring after Week 48 for participants not entering the post-Week 48 Open-Label phase of the study
DTG PK Parameters Including Cmax, Cmin, C0, and C0_avg
time frame: Week 4, Week 24, and Week 48
DTG PK Parameters Including AUC(0-tau)
time frame: Week 4, Week 24, and Week 48

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Antiretroviral therapy (ART)-experienced, Human Immunodeficiency Virus (HIV) -1 infected adults at least 18 years of age. - Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol). - HIV-1 infection as documented by HIV-1 RNA >400 copies/mL (c/mL) at Screening and with at least one consecutive HIV-1 RNA >400 c/mL within the four months prior to Screening (unless the Screening HIV-1 RNA is > 1000 c/mL where no additional plasma HIV-1 RNA assessment is needed). - Have documented resistance (via Screening resistance test) to two or more different classes of antiretroviral agents. For subjects off ART for at least one month, if Screening resistance results provide a fully active agent and do not show two class resistance then historical resistance results from the subject's most recent resistance testing may be used, following consultation with the study virologist and /or medical monitor. - Integrase inhibitor (INI)-naïve, defined as no prior exposure to any INI (e.g. RAL, elvitegravir, or GSK1349572). - Able to provide written informed consent prior to Screening. - French subjects: In France, subjects will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category. Exclusion Criteria: - Screening resistance test result indicates no fully active antiviral agents are available for design of the background regimen. - Subject-virus does not yield results using genotype/phenotype/tropism at Screening (assay data is essential for eligibility determination). - Women who are breastfeeding. - Any evidence of an active AIDS-defining condition (except cutaneous Kaposi's sarcoma not requiring systemic therapy or CD4+ <200c/mm3). - Subjects with moderate to severe hepatic impairment as defined by Child-Pugh classification. - Recent history (less than or equal to 3 months) of upper or lower gastrointestinal bleed, with the exception of anal or rectal bleeding. - Anticipated need for hepatitis C therapy during the study. - History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. - History of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma; other localized malignancies require agreement between the investigator and study medical monitor for inclusion of the subject. - Treatment with an HIV-1 immunotherapeutic vaccine within 90 days prior to Screening. - Treatment with any of the following agents within 28 days of Screening: radiation therapy, cytotoxic chemotherapeutic agents, any immunomodulator. - Treatment with any agent, other than licensed ART, which has documented activity against HIV-1 in vitro within 28 days of first dose of investigational product. - Exposure to an experimental drug and/or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the experimental test agent - whichever is longer, prior to the first dose of IP. - French subjects recruited at sites in France will be excluded if the subject has participated in any study using an investigational drug and/or vaccine within 60 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine - whichever is longer - prior to screening for the study or the subject plans to participate simultaneously in another clinical study. - Any acute or verified Grade 4 laboratory abnormality. - Alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN). - ALT greater than or equal to 3xULN and bilirubin greater than or equal to 1.5xULN (with >35% direct bilirubin).

Additional Information

Official title A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults
Description ING111762 is a 48 week, randomized, double-blind, active-controlled, multicenter, parallel group, non-inferiority study. The study will be conducted in at least 688 HIV-1 infected antiretroviral experienced, integrase-naïve subjects. Subjects will be randomized 1:1 to receive GSK1349572 50 mg once daily or raltegravir (RAL) 400 mg twice daily, each added to an investigator selected background regimen consisting of at least one fully active agent plus no more than one second single agent which may or may not be active. Antiviral activity, safety, pharmacokinetics (PK), and development of viral resistance will be evaluated. Subjects must have documented genotypic or phenotypic resistance to at least one member of each of at least two antiretroviral therapy (ART) drug classes [nucleoside/nucleotide reverse transcriptase inhibitor (N[t]RTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), protease inhibitor (PI), fusion inhibitor (T20), or entry inhibitor (chemokine receptor 5 [CCR5] antagonist)]. The primary analysis will take place after the last subject completes 48 weeks on therapy. An additional data cut and analysis will be conducted after the last subject completes 24 weeks on therapy. Subjects randomized to GSK1349572 who successfully complete Week 48 will continue to received GSK1349572 until either it is locally available, until they no longer derive clinical benefit, until they meet a protocol-defined reason for discontinuation, or until development of the compound is terminated. ViiV Healthcare is the sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship
Trial information was received from ClinicalTrials.gov and was last updated in March 2014.
Information provided to ClinicalTrials.gov by ViiV Healthcare.